Trial Profile
Phase 1/2 study of NS-065/NCNP-01 in patients with Duchenne muscular dystrophy
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 Aug 2020
Price :
$35
*
At a glance
- Drugs Viltolarsen (Primary)
- Indications Duchenne muscular dystrophy
- Focus Registrational; Therapeutic Use
- Sponsors Nippon Shinyaku
- 13 Aug 2020 According to an Nippon Shinyaku media release, the U.S. Food & Drug Administration (FDA) has approved VILTEPSO (viltolarsen) injection for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping therapy. DMD is a progressive muscle disease that primarily occurs in boys due to a genetic mutation in the dystrophin gene.
- 03 Oct 2018 Results published in the Nippon Shinyaku Media Release
- 03 Oct 2018 According to a Nippon Shinyaku media release, the results were presented at The 23rd International Annual Congress of the World Muscle Society 2018.